Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Garvey

Showing results (51-60 of 122) with videos related to

Pageof 13
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 28, 2017
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitorsChristopher M Yates, Edward P Garvey, Sammy R Shaver, et al.
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology|February 4, 2010
Ovarian inflammatory myofibroblastic tumour fistulating on to the anterior abdominal wallG Khan, A Treacy, J P Garvey, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2008
Increase in VTEC cases in the south of Ireland: link to private wells?M B O'Sullivan, P Garvey, M O'Riordan, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2018
The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitisE P Garvey, A D Sharp, P A Warn, et al.
Medical Mycology|April 3, 2024
Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598Kenan Gu, Robert Spitz, Erin Hammett, et al.
Nephrology (Carlton, Vic.)|November 12, 2010
A successful pregnancy in a dialysis patient with renal cortical necrosisCatherine M Brown, Claire O'Kane, Betty McDonnell, et al.
Journal of Medicinal Chemistry|June 6, 1997
Substituted N-phenylisothioureas: potent inhibitors of human nitric oxide synthase with neuronal isoform selectivityB G Shearer, S Lee, J A Oplinger, et al.
Antimicrobial Agents and Chemotherapy|January 22, 2015
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig modelE P Garvey, W J Hoekstra, W R Moore, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong <i>In Vitro</i> Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal CompoundsW A Schell, A M Jones, E P Garvey, et al.
Clinical Nephrology|October 30, 2009
Trimethoprim-sulfamethoxazole induced acute interstitial nephritis in renal allografts; clinical course and outcomeJ P Garvey, C M Brown, S H Chotirmall, et al.
Pageof 13

Showing results (51-60 of 122) with videos related to

Sort By:
Pageof 13
Bioorganic & Medicinal Chemistry Letters|June 28, 2017
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitorsChristopher M Yates, Edward P Garvey, Sammy R Shaver, et al.
Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology|February 4, 2010
Ovarian inflammatory myofibroblastic tumour fistulating on to the anterior abdominal wallG Khan, A Treacy, J P Garvey, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2008
Increase in VTEC cases in the south of Ireland: link to private wells?M B O'Sullivan, P Garvey, M O'Riordan, et al.
The Journal of Antimicrobial Chemotherapy|June 28, 2018
The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitisE P Garvey, A D Sharp, P A Warn, et al.
Medical Mycology|April 3, 2024
Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598Kenan Gu, Robert Spitz, Erin Hammett, et al.
Nephrology (Carlton, Vic.)|November 12, 2010
A successful pregnancy in a dialysis patient with renal cortical necrosisCatherine M Brown, Claire O'Kane, Betty McDonnell, et al.
Journal of Medicinal Chemistry|June 6, 1997
Substituted N-phenylisothioureas: potent inhibitors of human nitric oxide synthase with neuronal isoform selectivityB G Shearer, S Lee, J A Oplinger, et al.
Antimicrobial Agents and Chemotherapy|January 22, 2015
VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig modelE P Garvey, W J Hoekstra, W R Moore, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2016
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong <i>In Vitro</i> Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal CompoundsW A Schell, A M Jones, E P Garvey, et al.
Clinical Nephrology|October 30, 2009
Trimethoprim-sulfamethoxazole induced acute interstitial nephritis in renal allografts; clinical course and outcomeJ P Garvey, C M Brown, S H Chotirmall, et al.
Pageof 13